Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) Research & Development: 2020-2025

Historic Research & Development for iSpecimen (ISPC) over the last 6 years, with Sep 2025 value amounting to $551,104.

  • iSpecimen's Research & Development fell 26.98% to $551,104 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 27.13%. This contributed to the annual value of $3.5 million for FY2024, which is 1.03% down from last year.
  • iSpecimen's Research & Development amounted to $551,104 in Q3 2025, which was up 2.76% from $536,311 recorded in Q2 2025.
  • In the past 5 years, iSpecimen's Research & Development registered a high of $967,831 during Q4 2023, and its lowest value of $361,799 during Q2 2021.
  • In the last 3 years, iSpecimen's Research & Development had a median value of $843,099 in 2023 and averaged $793,635.
  • As far as peak fluctuations go, iSpecimen's Research & Development skyrocketed by 75.69% in 2022, and later slumped by 41.19% in 2025.
  • iSpecimen's Research & Development (Quarterly) stood at $522,551 in 2021, then soared by 41.69% to $740,410 in 2022, then surged by 30.72% to $967,831 in 2023, then declined by 1.67% to $951,667 in 2024, then fell by 26.98% to $551,104 in 2025.
  • Its Research & Development stands at $551,104 for Q3 2025, versus $536,311 for Q2 2025 and $545,367 for Q1 2025.